Franconi Rosella, Di Bonito Paola, Dibello Francesco, Accardi Luisa, Muller Antonio, Cirilli Alessia, Simeone Paola, Donà M Gabriella, Venuti Aldo, Giorgi Colomba
Ente per le Nuove Tecnologie, Energia e Ambiente, UTS Biotech, Sezione Genetica e Genomica Vegetale, CR Casaccia, Rome, Italy.
Cancer Res. 2002 Jul 1;62(13):3654-8.
Vaccine strategies for treatment of human papillomavirus-induced cervical cancer are based on either the recombinant E7 fusion oncoprotein or E7 CTL peptides. The therapeutic potential of the E7-based vaccine depends on the use of different adjuvants. In this study, we describe for the first time the expression of the human papillomavirus 16 E7 protein in Nicotiana benthamiana plant using a potato virus X-derived vector. C57BL/6 mice immunized with E7-containing crude foliar extracts developed both humoral and cell-mediated immune responses and were protected from tumor development after challenge with the E7-expressing C3 tumoral cell line. Our data support the possibility of producing a cost-effective anticancer vaccine in plant with intrinsic adjuvant-like properties.
用于治疗人乳头瘤病毒引发的宫颈癌的疫苗策略,基于重组E7融合癌蛋白或E7细胞毒性T淋巴细胞(CTL)肽。基于E7的疫苗的治疗潜力取决于不同佐剂的使用。在本研究中,我们首次描述了使用源自马铃薯X病毒的载体在本氏烟草植物中表达人乳头瘤病毒16 E7蛋白。用含E7的粗叶提取物免疫的C57BL/6小鼠产生了体液免疫和细胞介导的免疫反应,在用表达E7的C3肿瘤细胞系攻击后受到保护,免于肿瘤发展。我们的数据支持了在具有内在佐剂样特性的植物中生产具有成本效益的抗癌疫苗的可能性。